Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, April 5, 2023
[ Wed, Apr 05th 2023
] - WOPRAI
[ Wed, Apr 05th 2023
] - WOPRAI
[ Wed, Apr 05th 2023
] - WOPRAI
[ Wed, Apr 05th 2023
] - WOPRAI
Tue, April 4, 2023
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
[ Tue, Apr 04th 2023
] - WOPRAI
Vikram Purohit Downgraded (ASND) to Hold and Decreased Target to $108 on, Apr 4th, 2023
Vikram Purohit of Morgan Stanley, Downgraded "Ascendis Pharma A/S" (ASND) to Hold and Decreased Target from $151 to $108 on, Apr 4th, 2023.
Vikram has made no other calls on ASND in the last 4 months.
There are 3 other peers that have a rating on ASND. Out of the 3 peers that are also analyzing ASND, 1 agrees with Vikram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tiago Fauth of "Credit Suisse" Downgraded from Buy to Hold on, Monday, April 3rd, 2023
These are the ratings of the 2 analyists that currently disagree with Vikram
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $163 on, Tuesday, January 17th, 2023
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $177 on, Tuesday, January 3rd, 2023
